Health · 7 views
Another Unprecedented OS Win in Extensive-Stage SCLC With Tarlatamab Maintenance
(MedPage Today) -- Overall survival (OS) in extensive-stage small-cell lung cancer (ES-SCLC) approached 2 years with tarlatamab (Imdelltra) combination maintenance therapy after first-line chemoimmunotherapy, a large randomized trial…
Summary
(MedPage Today) -- Overall survival (OS) in extensive-stage small-cell lung cancer (ES-SCLC) approached 2 years with tarlatamab (Imdelltra) combination maintenance therapy after first-line chemoimmunotherapy, a large randomized trial showed.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Postpartum recovery window may play a critical role in maternal aging and long-term healthContinue reading
- The joy of veg-maxxing: how to eat many, many more plants – without really tryingContinue reading
- Execution Staff Warned That Christa Pike's IV Site Might Have 'Blown'Continue reading
- Ethnic minorities in England less likely to get breast cancer diagnosis from routine screeningContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow